BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
Citi initiated coverage on BeiGene Ltd BGNE with a price target of $275 and a Buy stock rating. The analyst notes that a detailed survey of 85 U.S. hematologists/oncologists suggests BeiGene's flagship asset Brukinsa is positioned to become the favored BTK inhibitor for Chronic lymphocytic…
#beigeneltd #beigene #btk #cll #fda #fl #citi #pharmacyclicsllc #pharmacyclics #abbvieincabbv